Daiken Medical Co., Ltd. (TYO:7775)
Japan
· Delayed Price · Currency is JPY 501.00
+1.00 (0.20%)
Mar 12, 2025, 3:30 PM JST
Daiken Medical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 10,010 | 9,750 | 9,137 | 8,540 | 7,861 | 8,523 | Upgrade
|
| Revenue Growth (YoY) | 3.76% | 6.71% | 6.99% | 8.64% | -7.77% | 1.39% | Upgrade
|
| Cost of Revenue | 5,882 | 5,768 | 5,607 | 4,856 | 4,503 | 4,789 | Upgrade
|
| Gross Profit | 4,127 | 3,982 | 3,530 | 3,684 | 3,358 | 3,734 | Upgrade
|
| Selling, General & Admin | 2,307 | 2,240 | 2,105 | 2,092 | 1,943 | 2,016 | Upgrade
|
| Research & Development | 249 | 249 | 316 | 382 | 448 | 488 | Upgrade
|
| Operating Expenses | 2,606 | 2,539 | 2,475 | 2,533 | 2,437 | 2,539 | Upgrade
|
| Operating Income | 1,522 | 1,443 | 1,055 | 1,151 | 921 | 1,195 | Upgrade
|
| Interest Expense | -6.71 | -4 | -3 | -3 | -3 | -4 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.04 | 2 | - | 1 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.97 | 5 | - | 3 | 38 | 17 | Upgrade
|
| EBT Excluding Unusual Items | 1,516 | 1,446 | 1,052 | 1,152 | 956 | 1,208 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2 | 2 | - | - | - | - | Upgrade
|
| Asset Writedown | -0.68 | -5 | -28 | -1 | - | -18 | Upgrade
|
| Other Unusual Items | -7.44 | -8 | - | - | -12 | - | Upgrade
|
| Pretax Income | 1,512 | 1,435 | 1,024 | 1,151 | 944 | 1,190 | Upgrade
|
| Income Tax Expense | 454.62 | 447 | 312 | 320 | 269 | 331 | Upgrade
|
| Net Income | 1,057 | 988 | 712 | 831 | 675 | 859 | Upgrade
|
| Net Income to Common | 1,057 | 988 | 712 | 831 | 675 | 859 | Upgrade
|
| Net Income Growth | 15.91% | 38.76% | -14.32% | 23.11% | -21.42% | 0.94% | Upgrade
|
| Shares Outstanding (Basic) | 29 | 29 | 29 | 29 | 29 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 29 | 29 | 29 | 29 | 29 | 29 | Upgrade
|
| Shares Change (YoY) | -0.00% | -0.00% | -0.00% | - | - | -2.00% | Upgrade
|
| EPS (Basic) | 36.80 | 34.39 | 24.78 | 28.93 | 23.50 | 29.90 | Upgrade
|
| EPS (Diluted) | 36.80 | 34.39 | 24.78 | 28.93 | 23.50 | 29.90 | Upgrade
|
| EPS Growth | 15.91% | 38.76% | -14.32% | 23.11% | -21.42% | 3.00% | Upgrade
|
| Free Cash Flow | - | 1,393 | 791 | 931 | 300 | 1,273 | Upgrade
|
| Free Cash Flow Per Share | - | 48.49 | 27.53 | 32.41 | 10.44 | 44.31 | Upgrade
|
| Gross Margin | - | 40.84% | 38.63% | 43.14% | 42.72% | 43.81% | Upgrade
|
| Operating Margin | 15.20% | 14.80% | 11.55% | 13.48% | 11.72% | 14.02% | Upgrade
|
| Profit Margin | 10.56% | 10.13% | 7.79% | 9.73% | 8.59% | 10.08% | Upgrade
|
| Free Cash Flow Margin | - | 14.29% | 8.66% | 10.90% | 3.82% | 14.94% | Upgrade
|
| EBITDA | 1,696 | 1,657 | 1,322 | 1,465 | 1,177 | 1,448 | Upgrade
|
| EBITDA Margin | - | 16.99% | 14.47% | 17.15% | 14.97% | 16.99% | Upgrade
|
| D&A For EBITDA | 174.25 | 214 | 267 | 314 | 256 | 253 | Upgrade
|
| EBIT | 1,522 | 1,443 | 1,055 | 1,151 | 921 | 1,195 | Upgrade
|
| EBIT Margin | - | 14.80% | 11.55% | 13.48% | 11.72% | 14.02% | Upgrade
|
| Effective Tax Rate | - | 31.15% | 30.47% | 27.80% | 28.50% | 27.82% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.